Jesús F. San Miguel, MD, PhD | Authors

Current Challenges in the Management of Patients with Relapsed/Refractory Multiple Myeloma

November 15, 2011

For patients with multiple myeloma (MM) who experience relapse, important advances in medical therapies in the past decade have doubled the duration of survival, mainly because of the effectiveness of novel agents such as thalidomide (Thalomid), bortezomib (Velcade), and lenalidomide (Revlimid).[1]